Naftopidil
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Naftopidil: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Naftopidil was originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are currently no clinical trials and no publications supporting this direction. The prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign prostatic hyperplasia |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data |
| Number of Listed Products | 4 (valid: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacological knowledge, naftopidil is an alpha-1 adrenergic receptor antagonist (preferentially alpha-1D) and is marketed for benign prostatic hyperplasia, where it relaxes smooth muscle in the prostate and bladder neck.
The link to the predicted indication is weak. Ambras syndrome is a congenital hypertrichosis linked to chromosome 8q regulatory rearrangements that affect TRPS1 expression. No direct mechanistic connection between alpha-1 adrenergic blockade and this genetic basis is evident. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other predictions in the same list (hypertrichosis in general, isolated genetic hair shaft abnormality, and several developmental malformation syndromes) show the same pattern: very high scores (0.9992 to 0.9995) with no supporting studies. For general hypertrichosis, the therapeutic goal (reducing versus promoting hair growth) would also need to be defined.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 153639 | Naftomax 50 Tablet | Strip of 10 tablets | Not stated in the data |
| 151226 | Nafodil 75 Tablet | Strip of 10 tablets | Not stated in the data |
| 150842 | Nafodil 50 Tablet | Strip of 10 tablets | Not stated in the data |
| 157282 | Naftomax 25 Tablet | Strip of 10 tablets | Not stated in the data |
All four registrations are valid single-ingredient oral tablets from Sun Pharmaceutical Industries Ltd (Naftomax) and Intas Pharmaceuticals Ltd (Nafodil). None has been cancelled.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no knowledge-graph contraindications were recorded.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score but no clinical trials, no literature, and no plausible mechanistic link between alpha-1 adrenergic blockade and the genetic cause of Ambras syndrome. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Detailed mechanism of action data for naftopidil (e.g., from DrugBank)
- Package insert warnings and contraindications from the India regulator, which are needed before any safety screening
- A defined biological hypothesis connecting alpha-1D adrenergic signalling to TRPS1-related or hair-follicle pathways
- Preclinical or case-level evidence supporting any effect on hair growth
- A clear therapeutic goal for hypertrichosis (reducing versus promoting hair growth)
- Assessment of route compatibility, since only oral tablets are currently available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.